During the initial two-year term of the agreement, which also provides Schering-Plough with the option of an extension of up to three more years, MorphoSys’s HuCAL GOLD® antibody library will be installed at Schering-Plough’s research site in Palo Alto, California, the location of Schering-Plough Biopharma, an affiliate of Schering-Plough Research Institute.
“The agreement signed today is our twelfth with a top 20 pharmaceutical company”, commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. “This deal marks further progress in the successful execution of our strategy to strengthen the pipeline of therapeutic antibodies based on our proprietary technology through strategic deals with quality partners.”